BASF's Share Buyback Strategy Aims to Counter Market Uncertainty

BASF raises savings target and executes buybacks, but cautious earnings forecast divides analysts from Buy to Underweight ratings ahead of key AGM.

In a challenging market environment, BASF is deploying multiple strategies to support its valuation. The chemical giant is sharpening its strategic focus through portfolio adjustments and has raised its internal cost-saving targets, all while executing a substantial share repurchase initiative. Despite these proactive measures, a cautious earnings forecast has revealed significant divisions among industry analysts.

Divergent Analyst Views Highlight Underlying Concerns

The contrast between the company's internal optimization efforts and external economic pressures is most evident in the wide range of analyst opinions:

• Goldman Sachs: Maintains a "Buy" rating with a 62 Euro price target, citing structural cost levers and long-term recovery potential.
• UBS: Rates the stock "Neutral," lowering its target slightly to 47 Euro due to persistent oversupply in core markets.
• J.P. Morgan: Assigns an "Underweight" rating with a 36 Euro target, pointing to a lack of clear signals for an earnings turnaround.

The next significant milestone for investors will be the Annual General Meeting in Mannheim on April 30, 2026. Management plans to propose a stable dividend of 2.25 Euro per share. This event will also feature the release of first-quarter results, providing the first concrete data on the progress of the savings program and the real impact of currency headwinds.

Buyback Program Advances Alongside Portfolio Reshaping

Recent updates on the multi-billion euro buyback program, which runs through 2028, provided positive momentum this week. The company purchased an additional 15,000 shares between March 16 and 20, bringing the total volume acquired since the program's inception in November 2025 to approximately 18.5 million shares.

Concurrently, BASF is streamlining its portfolio by divesting non-core assets. The sale of the Aseptrol technology portfolio to Oxidium is underway, while the divestment of the optical brighteners business to Catexel has already been completed. These moves are designed to concentrate resources and fuel growth in prioritized core segments. Bolstered by the buyback activity, the share price closed at 47.23 Euro on Tuesday, marking a moderate year-to-date gain of 5.57 percent.

Elevated Savings Goals Meet Subdued Earnings Guidance

On the operational front, management is intensifying its cost-cutting efforts. The savings target for the end of 2026 has been increased from 2.1 billion to 2.3 billion euros. However, the outlook for the current year remains a point of concern. The company's forecast for EBITDA before special items, set between 6.2 and 7.0 billion euros, falls below the average analyst consensus of 7.02 billion euros even at its upper range. Management identified a weaker US dollar as a key pressure point, noting that currency effects alone could create a negative impact of around 200 million euros in the first quarter.